Study gives insight into process of heart failure with preserved ejection fraction

Preliminary research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2024.

A prevalent kind of heart failure known as heart failure with intact ejection fraction happens when there are heart failure symptoms and signs associated with a high left ventricular filling pressure, even in the presence of a normal or nearly normal left ventricle ejection fraction of 50 per cent or more. When the heart's pumping power is 40% or less, it is said to have cardiac failure with diminished ejection fraction.

Healthy hearts require a high rate of adenosine triphosphate (ATP) production (provides the energy to drive and support the heart) to maintain their continuous pumping action. This energy comes from a balanced use of glucose and fats to support the heart's contractile function.

"Ketones are a special energy resource," said study author Qiuyu (Violet) Sun, B.Sc., a Ph.D. candidate at the University of Alberta in Canada. "Humans normally rely on carbohydrates and fat for energy. However, when blood glucose levels fall, such as after prolonged fasting or strenuous exercise, it poses a risk to our brain, which depends on glucose and cannot utilize fats for energy. To address this, our body has a built-in mechanism to produce this special energy substrate called ketones."

"This process is known as ketogenesis and involves breaking down fats from fat storage. The liver then converts these fats into ketone bodies, which enter the bloodstream to fuel the brain," Sun explained. "Ketones can convert the chemical energy in the form of ATP to improve the heart's pumping ability in a continuous fashion."

According to the researchers, relying on fatty acids to produce ATP could be problematic. Fatty acids are a less efficient fuel source compared to glucose because fats require more oxygen to produce the same amount of ATP as glucose.

In this study, researchers assessed mice hearts' metabolism and found that hearts with HFpEF reconstructed their metabolic profiles. Specifically, the researchers found in HFpEF hearts, ketone use was impaired, as well was also an impaired glucose oxidation rate coupled with an increase in fatty acid oxidation. These two changes balance each other, leading to overall preserved energy production.

When HFpEF hearts were given more ketones, this resulted in an increase in overall ATP production coming from ketones and glucose oxidation to ATP from 15% to 28% with preserved pumping ability. So, increasing ketone supply to the heart in HFpEF mice led to higher ATP production.

"This is crucial because this increase in ketone use by the heart did not cause any interference with glucose or fat use. In other words, ketones were not competing with glucose or fats as the energy source. As such, elevated ketone oxidation does not further aggravate the disrupted metabolic profile of the heart in HFpEF," Sun said.

According to the American Heart Association's 2024 Heart Disease and Stroke Statistics, an estimated 56.2 million people were living with heart failure across 204 countries globally in 2019. However, this estimate likely underrepresents the true rate of heart failure because of data and diagnostic gaps in low-resource regions and countries.

"The prevalence of heart failure with preserved ejection fraction is rising, driven by an aging population and increasing obesity rates. Unfortunately, there is still a lack of clinically effective treatment for this condition," Sun said. "We hope our study can help us better understand this condition. Identifying key proteins involved in cardiac energy metabolism could potentially lead to identification of druggable targets for future development of medications to treat HFpEF."

Sun said the next steps are to investigate the precise role of ketone use by the heart in HFpEF and to assess whether increasing the ketone supply to the heart could potentially optimize heart energy production and lead to improved cardiac function.

Study limitations were that it focused on the metabolic phenotype of HFpEF. However, there are different subgroups of HFpEF that possess varied clinical presentation, such as the fibrotic type or the diastolic dysfunction phenotypes of HFpEF. Both subgroups of HFpEF are of equal importance and should be investigated further. Additionally, because mice have different physiology and metabolic profiles than humans, future research should better characterize cardiac energy metabolism in HFpEF using experimental models that more closely align and translate to humans.